Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Bloomberg Natural Gas ETF (BOIL) vs Novavax Inc (NVAX) Price & Performance

ProShares Ultra Bloomberg Natural Gas ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Bloomberg Natural Gas ETF vs Novavax Inc — how do they compare? ProShares Ultra Bloomberg Natural Gas ETF trades at $20.73, while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: Novavax Inc is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.

BOILNVAX
Sector
Leveraged / InverseHealth
52-Week High
$87.24$11.19
52-Week Low
$18.74$6.22
Market Cap
$1.31B
Enterprise Value
$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Bloomberg Natural Gas ETF

BOIL trades at $20.91, up 0.97% with a bearish technical signal as moving averages indicate selling pressure. The stock recently underwent a 1:2 split effective May 28, 2026. Natural gas market volatility and weather-driven demand fluctuations create trading opportunities, though financial fundamentals remain undisclosed in current data.

Outlook hinges on natural gas price movements and energy sector dynamics. Investment appeal lies in leveraged exposure to gas futures via the ETF structure, but risks include commodity price swings and lack of traditional corporate fundamentals. Bearish technicals suggest cautious entry points near support at $20.

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

About ProShares Ultra Bloomberg Natural Gas ETF

BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.

Read more on BOIL

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX